You are here: Industry Insights > solid tumours

News List

GSK's Jemperli scores FDA nod for mismatch repair-deficient solid tumours firstwordpharma
August 18, 2021
GlaxoSmithKline said the FDA has expanded the label for Jemperli (dostarlimab-gxly) to include treatment of adults with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours.
Novartis, TScan collaborate to develop TCR therapies for solid tumours pharmaceutical-business-review
April 20, 2020
Novartis has collaborated with TScan Therapeutics for the discovery and development of T cell receptor (TCR) therapies to treat solid tumours.
Innovent and Hutchison to test sintilimab and fruquintinib combination pharmaceutical-technology
December 03, 2018
Innovent Biologics (Suzhou) has entered into a global collaboration agreement to evaluate the safety of its sintilimab in combination with Hutchison MediPharma’s fruquintinib .....
Boehringer Ingelheim acquires MabVax’s programme for solid tumours pharmaceutical-technology
July 12, 2018
Boehringer Ingelheim has entered an asset acquisition and licence agreement for US-based biotechnology firm MabVax Therapeutics’ programme designed to target a glycan that is commonly overexpressed on various solid tumours cancers.
Seattle Genetics exercises option to co-develop tisotumab vedotin for solid tumours pharmaceutical-technology
August 31, 2017
Danish biotechnology company Genmab and US-based Seattle Genetics are set to co-develop tisotumab vedotin for the treatment of patients with solid tumours.